a paper from our group has been published titled “image quality evaluation for a clinical organ-targeted pet camera” in frontiers in oncology (volume: 14, march 2024). congratulations on the published paper!

introduction: a newly developed clinical organ-targeted positron emission tomography (pet) system (also known as radialis pet) is tested with a set of standardized and custom tests previously used to evaluate the performance of positron emission mammography (pem) systems.
methods: imaging characteristics impacting standardized uptake value (suv) and detectability of small lesions, namely spatial resolution, linearity, uniformity, and recovery coefficients, are evaluated.
results: in-plane spatial resolution was measured as 2.3 mm ± 0.1 mm, spatial accuracy was 0.1 mm, and uniformity measured with flood field and nema nu-4 phantom was 11.7% and 8.3% respectively. selected clinical images are provided as reference to the imaging capabilities under different clinical conditions such as reduced activity of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (18f-fdg) and time-delayed acquisitions. suv measurements were performed for selected clinical acquisitions to demonstrate a capability for quantitative image assessment of different types of cancer including for invasive lobular carcinoma with comparatively low metabolic activity. quantitative imaging performance assessment with phantoms demonstrates improved contrast recovery and spill-over ratio for this pet technology when compared to other commercial organ-dedicated pet systems with similar spatial resolution. recovery coefficients were measured to be 0.21 for the 1 mm hot rod and up to 0.89 for the 5 mm hot rod of nema nu-4 image quality phantom.
discussion: demonstrated ability to accurately reconstruct activity in tumors as small as 5 mm suggests that the radialis pet technology may be well suited for emerging clinical applications such as image guided assessment of response to neoadjuvant systemic treatment (nst) in lesions smaller than 2 cm. also, our results suggest that, while spatial resolution greatly influences the partial volume effect which degrades contrast recovery, optimized count rate performance and image reconstruction workflow may improve recovery coefficients for systems with comparable spatial resolution. we emphasize that recovery coefficient should be considered as a primary performance metric when a pet system is used for accurate lesion size or radiotracer uptake assessments.

continue reading the article: https://doi.org/10.3389/fonc.2024.1268991

the post new publication: image quality evaluation for a clinical organ-targeted pet camera in frontiers in oncology appeared first on rezniklab and posted by pavlo karasyuk.

date: february 12, 2024

an article has been published, in radiology: imaging cancer, reporting results from a pilot study including newly diagnosed breast cancer patients with the low-dose positron emission mammography system developed by our collaborator, radialis. see the article here.
in addition, a commentary, titled “low-dose positron emission mammography: a novel, promising technique for breast cancer detection” has been written, which discusses findings from this study and highlights their importance. see the commentary here.

the post clinical findings using a low-dose pem system appeared first on rezniklab and posted by pavlo karasyuk.

radialis medical’s medical chief technology officer, sasha bubon, was presented mitacs nrc irap award for commercialization for his astounding efforts and accomplishments in developing a lower-dose pet device for high-resolution imaging mammography. more information.

the post congratulations to sasha bubon on mitacs nrc irap award for commercialization appeared first on rezniklab and posted by pavlo karasyuk.

breast cancer accounts for approximately 26% of all cancers diagnosed today. like other cancers, breast cancer is most successfully treated if the disease is diagnosed early. the major problem is distinguishing between benign and malignant masses. women are forced to contemplate prophylactic mastectomy because predictive power of current imaging is poor.
radialis corporation (a spin-off company of the tbrhri and 阿根廷vs墨西哥竞猜 ) is manufacturing an advanced positron emission mammography (pem) system for molecular (or functional) imaging of breast cancer. pem detects small cancerous breast lesions based on their increased glucose metabolism and such its imaging performance is inherently independent on breast tissue density.
the core technology of the pem system was developed in our research laboratory under the supervision of dr. alla reznik. radialis pem employs 2 planar high-resolution detector heads placed on both sides of gently steadied breast (see figure above). pem only requires breast immobilization rather than compression and hence completely eliminates pain. during image acquisition, detectors fully cover the entire breast that allows for improved sensitivity capable of significant radiation dose reduction in comparison with commercially available scanners. large field-of-view detector design enables high-resolution. tumors as small as 1.2 mm will be detectable by the initial results of radials’s pem system.
radialis’s pem technology can be used as an adjuvant technique for breast cancer detection, and an integral part of the surveillance protocol of women at high and intermediate lifetime risk of breast cancer. technological advances used will reduce manufacturing cost for pem devices, thus positively influence people health.

for more information, please see an article “using positron emission mammography to detect breast cancer” or our latest publication on the topic: “evaluation of a high-sensitivity organ-targeted pet camera”.

the post low-dose organ-targeted positron emission tomography appeared first on rezniklab and posted by pavlo karasyuk.